original ) (raw )Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter Taylor
Rheumatology, 2019
View PDFchevron_right
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis
Patrice Decker
Expert Opinion on Investigational Drugs, 2016
View PDFchevron_right
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Paul Langley
INNOVATIONS in pharmacy, 2020
View PDFchevron_right
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Alan Kivitz
The Journal of Rheumatology, 2014
View PDFchevron_right
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside
Yoshiya Tanaka
Journal of Biochemistry, 2015
View PDFchevron_right
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark Genovese
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
Januskinase Inhibitors to Treat Rheumatoid Arthritis: Real World Data Match Clinical Trial Results. An Evaluation by BioReg, the Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS in the Treatment of Inflammatory Rheumatic Diseases
Burkhard Leeb
2021
View PDFchevron_right
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Francesco Scaglione
Biomolecules, 2020
View PDFchevron_right
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Kay Myint , Soe Moe
ISRN Rheumatology, 2013
View PDFchevron_right
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Namita Tundia
Advances in Therapy
View PDFchevron_right
OP0122 COMPARATIVE Effectiveness of Jaki Versus Bdmards; a Nationwide Study in Ra
Katerina Chatzidionysiou
Annals of the Rheumatic Diseases
View PDFchevron_right
Janus Kinase Enzyme (Jak) Inhibitors and Rheumatoid Arthritis: A Review of the Literature
hana morrissey
International Journal of Current Pharmaceutical Research
View PDFchevron_right
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy
Paul Emery
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Namita Tundia
Advances in Therapy
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
Erika García , Karina Santana , Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Mykola Stanislavchuk
Annals of the Rheumatic Diseases, 2016
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jamie Geier
Annals of the rheumatic diseases, 2015
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Erika García , Karina Santana , Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Przemyslaw Kotyla
BioMed Research International
View PDFchevron_right
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
Giuseppe Turchetti
Pharmaceuticals, 2023
View PDFchevron_right
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Nandini Kishore
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Yoshiya Tanaka
Annals of the rheumatic diseases, 2015
View PDFchevron_right
Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis
Mark Genovese
Arthritis & rheumatology (Hoboken, N.J.), 2017
View PDFchevron_right
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Andrzej Pilc
Clinical Rheumatology, 2013
View PDFchevron_right
JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
Yasmin Adel
The Egyptian Journal of Internal Medicine, 2021
View PDFchevron_right
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors
Francesca Marino
Expert review of clinical immunology, 2018
View PDFchevron_right
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
Joel Kremer
Arthritis & Rheumatism, 2012
View PDFchevron_right